A
12.36
-0.14 (-1.12%)
| Previous Close | 12.50 |
| Open | 12.56 |
| Volume | 1,509,931 |
| Avg. Volume (3M) | 3,005,100 |
| Market Cap | 1,870,767,872 |
| Price / Earnings (Forward) | 62.11 |
| Price / Sales | 2.50 |
| Price / Book | 154.95 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | -25.77% |
| Operating Margin (TTM) | -18.74% |
| Diluted EPS (TTM) | -1.14 |
| Quarterly Revenue Growth (YOY) | 22.20% |
| Total Debt/Equity (MRQ) | 6,465.30% |
| Current Ratio (MRQ) | 2.76 |
| Operating Cash Flow (TTM) | -11.25 M |
| Levered Free Cash Flow (TTM) | -24.32 M |
| Return on Assets (TTM) | -9.33% |
| Return on Equity (TTM) | -291.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Alphatec Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | 3.0 |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.40 |
|
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 21.42% |
| % Held by Institutions | 63.24% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 27.00 (Barclays, 118.45%) | Buy |
| Median | 23.00 (86.08%) | |
| Low | 20.00 (Stifel, 61.81%) | Buy |
| Average | 23.25 (88.11%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 17.51 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 09 Mar 2026 | 20.00 (61.81%) | Buy | 12.87 |
| HC Wainwright & Co. | 12 Jan 2026 | 24.00 (94.17%) | Buy | 17.59 |
| Needham | 12 Jan 2026 | 22.00 (77.99%) | Buy | 17.59 |
| Barclays | 07 Jan 2026 | 27.00 (118.45%) | Buy | 21.97 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KONING JOHN TODD | - | 12.28 | -79,789 | -979,809 |
| LISH SCOTT | - | 12.28 | -260,535 | -3,199,370 |
| SPONSEL DAVID | - | 12.66 | -163,452 | -2,069,302 |
| Aggregate Net Quantity | -503,776 | |||
| Aggregate Net Value ($) | -6,248,481 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 12.41 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LISH SCOTT | Officer | 13 Mar 2026 | Sell (-) | 260,535 | 12.28 | 3,199,370 |
| KONING JOHN TODD | Officer | 13 Mar 2026 | Automatic sell (-) | 79,789 | 12.28 | 979,809 |
| SPONSEL DAVID | Officer | 11 Mar 2026 | Automatic sell (-) | 163,452 | 12.66 | 2,069,302 |
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | ATEC and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion |
| 12 Jan 2026 | Announcement | ATEC Announces Select Preliminary Financial Results for 2025 and Provides 2026 Outlook |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |